Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
204.59M | 306.91M | 369.19M | 583.19M | 614.06M | Gross Profit |
81.38M | 165.54M | 242.48M | 461.86M | 482.62M | EBIT |
-91.80M | -67.59M | -92.34M | 22.28M | -19.66M | EBITDA |
-74.18M | -50.90M | -100.65M | 14.28M | -12.71M | Net Income Common Stockholders |
-82.18M | -59.11M | -105.80M | 7.73M | -18.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
294.22M | 320.66M | 309.36M | 454.13M | 500.93M | Total Assets |
685.35M | 831.68M | 886.18M | 1.07B | 966.02M | Total Debt |
7.72M | 8.74M | 10.02M | 8.58M | 9.15M | Net Debt |
-113.31M | -190.51M | -207.65M | -210.88M | -177.81M | Total Liabilities |
199.17M | 279.59M | 290.85M | 400.97M | 338.52M | Stockholders Equity |
486.18M | 552.10M | 595.33M | 667.10M | 627.50M |
Cash Flow | Free Cash Flow | |||
-31.02M | 6.35M | -180.69M | ― | -22.00M | Operating Cash Flow |
-31.02M | 6.88M | -180.09M | -66.54M | -21.75M | Investing Cash Flow |
-45.98M | -25.52M | 175.29M | 104.10M | -376.96M | Financing Cash Flow |
-1.40K | 230.00K | -379.00K | -5.07M | -58.91M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $199.33M | 49.54 | 7.41% | ― | 26.86% | ― | |
59 Neutral | $219.42M | 127.79 | 2.17% | ― | 134.52% | ― | |
53 Neutral | $5.14B | 3.03 | -44.09% | 2.83% | 16.75% | -0.06% | |
51 Neutral | $230.18M | ― | -17.22% | ― | -22.93% | -65.68% | |
47 Neutral | $230.77M | ― | 322.49% | ― | -30.66% | 36.48% | |
44 Neutral | $161.67M | ― | -32.97% | ― | ― | ― | |
38 Underperform | $121.35M | ― | -262.12% | ― | 239.92% | 79.41% |
At Amarin Corporation’s Annual General Meeting on May 13, 2025, shareholders voted on several proposals, with all but Proposal 12 being approved. Proposal 12, which aimed to allow the Board to allot 10% of the company’s share capital without statutory pre-emption rights, did not receive the necessary shareholder approval despite recommendations from ISS and Glass Lewis. This rejection necessitates the Board to explore alternative compensation arrangements for non-employee directors, potentially impacting the company’s cash position.
The most recent analyst rating on (AMRN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Amarin stock, see the AMRN Stock Forecast page.
On April 29, 2025, Amarin Corporation announced it has regained compliance with Nasdaq’s minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market. This compliance was achieved following an adjustment in the ratio of its American Depositary Shares to ordinary shares. The company remains committed to maximizing the global value of its primary product, VASCEPA/VAZKEPA, for cardiovascular disease management.
On April 9, 2025, Amarin announced a change in the ratio of its American Depositary Shares (ADS) to ordinary shares, effective April 11, 2025, to maintain its Nasdaq listing. This adjustment, resulting in a one-for-twenty reverse split of ADSs, aims to increase the per-share market price to meet Nasdaq’s minimum bid requirement, although the company cannot guarantee the expected price increase.
On April 4, 2025, Amarin Corporation appointed Michael Torok to its Board of Directors. Torok, co-founder of JEC Capital Partners, brings financial expertise and a focus on maximizing shareholder value. His appointment is expected to strengthen Amarin’s strategic direction and shareholder engagement.
On March 25, 2025, Amarin Corporation plc announced that Mr. Mark DiPaolo has decided not to stand for re-election at the 2025 Annual Meeting of Shareholders, scheduled for May 2025. Mr. DiPaolo’s departure from the Board of Directors is not due to any disagreements with the company’s operations, policies, or practices.
On March 12, 2025, Amarin announced a 1-for-20 reverse split of its American depositary shares (ADSs) to maintain its Nasdaq listing, effective around April 11, 2025. This move is expected to proportionally increase the trading price of its ADSs, although no assurance is given that the price will be 20 times higher post-split. In 2024, Amarin reported $62.3 million in fourth-quarter revenue, a 17% decrease from the previous year, primarily due to U.S. generic competition. Despite this, the company made significant progress in expanding its VASCEPA/VAZKEPA franchise globally, securing reimbursements in Italy and Austria, and advancing commercialization efforts in other markets.